Australia External Counterpulsation Devices Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
Description
Australia External Counterpulsation Devices Market Overview
The Australia External Counterpulsation Devices Market is valued at AUD 10 million, based on a five-year historical analysis and by benchmarking against the global external counterpulsation / EECP devices market and Australia’s share of the broader cardiovascular devices market. This growth is primarily driven by the increasing prevalence of cardiovascular diseases in Australia, rising awareness about non?invasive treatment options such as EECP for refractory angina and heart failure symptoms, and ongoing advancements in medical technology that enhance the efficacy and clinical adoption of external counterpulsation therapy. Key cities such as Sydney, Melbourne, and Brisbane dominate the market due to their advanced healthcare infrastructure, high concentration of tertiary cardiac care facilities, and a growing population of elderly individuals who are more susceptible to cardiovascular conditions. These factors contribute to a robust demand for external counterpulsation devices in these regions, supported by the presence of leading hospitals, specialist cardiology practices, and cardiac rehabilitation networks that are more likely to integrate EECP into multimodal management pathways for chronic coronary syndromes and heart failure patients. In 2023, the Australian government continued to strengthen regulations to ensure the safety and efficacy of medical devices, including external counterpulsation systems, under the Therapeutic Goods (Medical Devices) Regulations 2002 issued by the Australian Government and administered by the Therapeutic Goods Administration (TGA). This regulatory framework mandates that all medical devices must comply with the Essential Principles, undergo appropriate conformity assessment procedures, and be included in the Australian Register of Therapeutic Goods (ARTG) before being supplied for clinical use, thereby enhancing patient safety and promoting the adoption of high?quality medical technologies such as EECP systems.
Australia External Counterpulsation Devices Market Segmentation
By Product: The product segmentation includes EECP Systems and Accessories & Consumables (cuffs, hoses, ECG leads, others). The EECP systems are the primary focus due to their effectiveness in treating various cardiovascular conditions such as chronic stable angina and symptoms related to heart failure and left ventricular dysfunction, while accessories and consumables support the functionality, patient comfort, and ongoing usability of these systems during repeated treatment sessions. The EECP Systems segment dominates the market due to their proven effectiveness in treating refractory angina and improving overall cardiovascular health, with EECP recognized as a non?invasive, FDA?approved therapy for chronic stable angina and used internationally as an adjunctive option in patients not suitable for revascularisation. The increasing adoption of these systems in hospitals and outpatient clinics, coupled with a growing body of clinical and real?world evidence supporting their use for symptom relief, functional capacity improvement and quality?of?life gains, has led to a significant rise in demand. Additionally, the trend towards non?invasive and cost?effective treatment options in cardiovascular care, including interest in EECP for indications such as microvascular angina and post?COVID?19 cardiovascular symptom management, has further solidified the position of EECP systems as a preferred choice among healthcare providers looking to expand therapeutic options beyond pharmacologic and interventional procedures. By Mobility: The mobility segmentation includes Fixed Systems and Mobile / Portable Systems. Fixed systems are typically used in hospitals and cardiac centers, where they are integrated into dedicated EECP suites or cardiac rehabilitation units, while mobile systems offer flexibility for outpatient settings, satellite clinics, and potentially supervised home?based programs in selected patients. Fixed Systems lead the market due to their widespread use in hospitals and cardiac centers, where they are integrated into comprehensive cardiac care programs, including multidisciplinary management of complex angina and heart failure patients. The reliability, higher throughput capacity, and advanced monitoring and safety features of fixed systems make them the preferred choice for healthcare providers handling higher patient volumes. However, the growing trend towards home care, ambulatory cardiac rehabilitation, and decentralized outpatient services is driving the demand for Mobile / Portable Systems, which offer convenience, improved access in regional areas, and scheduling flexibility for patients undergoing EECP treatment outside traditional tertiary care settings.
Australia External Counterpulsation Devices Market Market Opportunities
The Australia External Counterpulsation Devices Market is characterized by a dynamic mix of regional and international players. Leading participants such as Vaso Corporation, Renew Group Private Limited, ScottCare Cardiovascular Solutions, Vasomedical Inc., ACS Diagnostics Inc., Shenzhen Deyilong Technology Co., Ltd., Shanghai Goodmed Medical Device Co., Ltd., Medtronic plc (Australia Operations), Abbott Laboratories (Australia Operations), Boston Scientific Corporation (Australia Operations), GE HealthCare (Australia & New Zealand), Siemens Healthineers (Australia & New Zealand), Canon Medical Systems Corporation (Oceania), Local Cardiac Rehabilitation & EECP Clinics Network, Emerging Domestic EECP Technology Start?ups contribute to innovation, geographic expansion, and service delivery in this space.
Vaso Corporation
1987 Plainview, New York, USA
Renew Group Private Limited
2008
Singapore
ScottCare Cardiovascular Solutions
1989 Cleveland, Ohio, USA
Vasomedical Inc. 1995 Plainview, New York, USA
ACS Diagnostics Inc. 1987 Irvine, California, USA
Company
Establishment Year
Headquarters
Company Size (Global revenue band: Large, Mid, Emerging) Australia EECP Revenue (AUD, latest year)
3?Year Australia EECP Revenue CAGR
Installed Base in Australia (number of EECP units)
New Installations per Year in Australia
Market Share in Australia EECP Devices (%)
Australia External Counterpulsation Devices Market Industry Analysis
Growth Drivers
Increasing Prevalence of Cardiovascular Diseases: The Australian Bureau of Statistics reported that cardiovascular diseases affect approximately 1.2 million Australians, accounting for around one in four deaths in the country. This alarming statistic drives the demand for effective treatment options, including external counterpulsation devices. With the healthcare expenditure projected to continue rising in future, the focus on innovative therapies to manage cardiovascular conditions is expected to intensify, further propelling market growth. Rising Awareness About Non-Invasive Treatment Options: A survey by the Heart Foundation indicated that 70% of Australians are now aware of non-invasive treatments for heart diseases. This growing awareness is crucial as it encourages patients to seek alternatives to traditional surgical procedures. The Australian healthcare system is increasingly promoting non-invasive therapies, which are expected to see a rise in adoption, thereby enhancing the market for external counterpulsation devices significantly. Technological Advancements in Medical Devices: The Australian medical device market is projected to grow to AUD 12 billion by 2024, driven by innovations in technology. Recent advancements in external counterpulsation devices, such as improved efficacy and user-friendly designs, are attracting healthcare providers. The integration of smart technologies and data analytics into these devices is enhancing patient outcomes, making them more appealing to both practitioners and patients, thus driving market growth.
Market Challenges
High Cost of Devices: The average cost of external counterpulsation devices in Australia ranges from AUD 30,000 to AUD 50,000, which poses a significant barrier to adoption. Many healthcare facilities, especially smaller clinics, struggle to justify such high capital expenditures. This financial constraint limits the availability of these devices, hindering market penetration and growth, particularly in rural areas where healthcare budgets are tighter. Limited Reimbursement Policies: According to the Australian Government Department of Health, reimbursement for external counterpulsation therapy is limited, with only a few private health insurers covering these treatments. This lack of comprehensive reimbursement policies discourages healthcare providers from investing in these devices, as patients may be unable to afford out-of-pocket expenses. Consequently, this challenge restricts market growth and accessibility for patients in need of such therapies.
Australia External Counterpulsation Devices Market Future Outlook
The future of the external counterpulsation devices market in Australia appears promising, driven by an increasing focus on preventive healthcare and personalized medicine. As the healthcare landscape evolves, the integration of artificial intelligence and telemedicine is expected to enhance patient monitoring and treatment efficacy. Furthermore, the expansion of healthcare infrastructure will facilitate greater access to these devices, ensuring that more patients can benefit from non-invasive cardiovascular treatments in the coming years.
Market Opportunities
Expansion of Healthcare Infrastructure: The Australian government plans to invest AUD 5 billion in healthcare infrastructure in future, which will enhance access to advanced medical technologies. This investment is likely to create opportunities for external counterpulsation devices, as more facilities will be equipped to offer these innovative treatments, ultimately benefiting patient care and market growth. Increasing Investment in R&D: The Australian medical research sector is projected to receive AUD 1.5 billion in funding in future, focusing on innovative healthcare solutions. This influx of investment will likely spur advancements in external counterpulsation technology, leading to improved device efficacy and patient outcomes. As research progresses, new applications for these devices may emerge, further expanding their market potential.
Please Note: The report will take approximately 4–6 weeks to prepare and deliver.
Update cycle typically involves:
Dataset refresh & triangulation from credible public sources + paid databases where applicable.
Competitive mapping (platform coverage, business model, revenue/traffic proxies where available, key vertical splits)
Validation pass to ensure numbers are directionally consistent (and avoid “stale” assumptions)
Finalizing the PDF + Excel with clear assumptions and definitions.
The Australia External Counterpulsation Devices Market is valued at AUD 10 million, based on a five-year historical analysis and by benchmarking against the global external counterpulsation / EECP devices market and Australia’s share of the broader cardiovascular devices market. This growth is primarily driven by the increasing prevalence of cardiovascular diseases in Australia, rising awareness about non?invasive treatment options such as EECP for refractory angina and heart failure symptoms, and ongoing advancements in medical technology that enhance the efficacy and clinical adoption of external counterpulsation therapy. Key cities such as Sydney, Melbourne, and Brisbane dominate the market due to their advanced healthcare infrastructure, high concentration of tertiary cardiac care facilities, and a growing population of elderly individuals who are more susceptible to cardiovascular conditions. These factors contribute to a robust demand for external counterpulsation devices in these regions, supported by the presence of leading hospitals, specialist cardiology practices, and cardiac rehabilitation networks that are more likely to integrate EECP into multimodal management pathways for chronic coronary syndromes and heart failure patients. In 2023, the Australian government continued to strengthen regulations to ensure the safety and efficacy of medical devices, including external counterpulsation systems, under the Therapeutic Goods (Medical Devices) Regulations 2002 issued by the Australian Government and administered by the Therapeutic Goods Administration (TGA). This regulatory framework mandates that all medical devices must comply with the Essential Principles, undergo appropriate conformity assessment procedures, and be included in the Australian Register of Therapeutic Goods (ARTG) before being supplied for clinical use, thereby enhancing patient safety and promoting the adoption of high?quality medical technologies such as EECP systems.
Australia External Counterpulsation Devices Market Segmentation
By Product: The product segmentation includes EECP Systems and Accessories & Consumables (cuffs, hoses, ECG leads, others). The EECP systems are the primary focus due to their effectiveness in treating various cardiovascular conditions such as chronic stable angina and symptoms related to heart failure and left ventricular dysfunction, while accessories and consumables support the functionality, patient comfort, and ongoing usability of these systems during repeated treatment sessions. The EECP Systems segment dominates the market due to their proven effectiveness in treating refractory angina and improving overall cardiovascular health, with EECP recognized as a non?invasive, FDA?approved therapy for chronic stable angina and used internationally as an adjunctive option in patients not suitable for revascularisation. The increasing adoption of these systems in hospitals and outpatient clinics, coupled with a growing body of clinical and real?world evidence supporting their use for symptom relief, functional capacity improvement and quality?of?life gains, has led to a significant rise in demand. Additionally, the trend towards non?invasive and cost?effective treatment options in cardiovascular care, including interest in EECP for indications such as microvascular angina and post?COVID?19 cardiovascular symptom management, has further solidified the position of EECP systems as a preferred choice among healthcare providers looking to expand therapeutic options beyond pharmacologic and interventional procedures. By Mobility: The mobility segmentation includes Fixed Systems and Mobile / Portable Systems. Fixed systems are typically used in hospitals and cardiac centers, where they are integrated into dedicated EECP suites or cardiac rehabilitation units, while mobile systems offer flexibility for outpatient settings, satellite clinics, and potentially supervised home?based programs in selected patients. Fixed Systems lead the market due to their widespread use in hospitals and cardiac centers, where they are integrated into comprehensive cardiac care programs, including multidisciplinary management of complex angina and heart failure patients. The reliability, higher throughput capacity, and advanced monitoring and safety features of fixed systems make them the preferred choice for healthcare providers handling higher patient volumes. However, the growing trend towards home care, ambulatory cardiac rehabilitation, and decentralized outpatient services is driving the demand for Mobile / Portable Systems, which offer convenience, improved access in regional areas, and scheduling flexibility for patients undergoing EECP treatment outside traditional tertiary care settings.
Australia External Counterpulsation Devices Market Market Opportunities
The Australia External Counterpulsation Devices Market is characterized by a dynamic mix of regional and international players. Leading participants such as Vaso Corporation, Renew Group Private Limited, ScottCare Cardiovascular Solutions, Vasomedical Inc., ACS Diagnostics Inc., Shenzhen Deyilong Technology Co., Ltd., Shanghai Goodmed Medical Device Co., Ltd., Medtronic plc (Australia Operations), Abbott Laboratories (Australia Operations), Boston Scientific Corporation (Australia Operations), GE HealthCare (Australia & New Zealand), Siemens Healthineers (Australia & New Zealand), Canon Medical Systems Corporation (Oceania), Local Cardiac Rehabilitation & EECP Clinics Network, Emerging Domestic EECP Technology Start?ups contribute to innovation, geographic expansion, and service delivery in this space.
Vaso Corporation
1987 Plainview, New York, USA
Renew Group Private Limited
2008
Singapore
ScottCare Cardiovascular Solutions
1989 Cleveland, Ohio, USA
Vasomedical Inc. 1995 Plainview, New York, USA
ACS Diagnostics Inc. 1987 Irvine, California, USA
Company
Establishment Year
Headquarters
Company Size (Global revenue band: Large, Mid, Emerging) Australia EECP Revenue (AUD, latest year)
3?Year Australia EECP Revenue CAGR
Installed Base in Australia (number of EECP units)
New Installations per Year in Australia
Market Share in Australia EECP Devices (%)
Australia External Counterpulsation Devices Market Industry Analysis
Growth Drivers
Increasing Prevalence of Cardiovascular Diseases: The Australian Bureau of Statistics reported that cardiovascular diseases affect approximately 1.2 million Australians, accounting for around one in four deaths in the country. This alarming statistic drives the demand for effective treatment options, including external counterpulsation devices. With the healthcare expenditure projected to continue rising in future, the focus on innovative therapies to manage cardiovascular conditions is expected to intensify, further propelling market growth. Rising Awareness About Non-Invasive Treatment Options: A survey by the Heart Foundation indicated that 70% of Australians are now aware of non-invasive treatments for heart diseases. This growing awareness is crucial as it encourages patients to seek alternatives to traditional surgical procedures. The Australian healthcare system is increasingly promoting non-invasive therapies, which are expected to see a rise in adoption, thereby enhancing the market for external counterpulsation devices significantly. Technological Advancements in Medical Devices: The Australian medical device market is projected to grow to AUD 12 billion by 2024, driven by innovations in technology. Recent advancements in external counterpulsation devices, such as improved efficacy and user-friendly designs, are attracting healthcare providers. The integration of smart technologies and data analytics into these devices is enhancing patient outcomes, making them more appealing to both practitioners and patients, thus driving market growth.
Market Challenges
High Cost of Devices: The average cost of external counterpulsation devices in Australia ranges from AUD 30,000 to AUD 50,000, which poses a significant barrier to adoption. Many healthcare facilities, especially smaller clinics, struggle to justify such high capital expenditures. This financial constraint limits the availability of these devices, hindering market penetration and growth, particularly in rural areas where healthcare budgets are tighter. Limited Reimbursement Policies: According to the Australian Government Department of Health, reimbursement for external counterpulsation therapy is limited, with only a few private health insurers covering these treatments. This lack of comprehensive reimbursement policies discourages healthcare providers from investing in these devices, as patients may be unable to afford out-of-pocket expenses. Consequently, this challenge restricts market growth and accessibility for patients in need of such therapies.
Australia External Counterpulsation Devices Market Future Outlook
The future of the external counterpulsation devices market in Australia appears promising, driven by an increasing focus on preventive healthcare and personalized medicine. As the healthcare landscape evolves, the integration of artificial intelligence and telemedicine is expected to enhance patient monitoring and treatment efficacy. Furthermore, the expansion of healthcare infrastructure will facilitate greater access to these devices, ensuring that more patients can benefit from non-invasive cardiovascular treatments in the coming years.
Market Opportunities
Expansion of Healthcare Infrastructure: The Australian government plans to invest AUD 5 billion in healthcare infrastructure in future, which will enhance access to advanced medical technologies. This investment is likely to create opportunities for external counterpulsation devices, as more facilities will be equipped to offer these innovative treatments, ultimately benefiting patient care and market growth. Increasing Investment in R&D: The Australian medical research sector is projected to receive AUD 1.5 billion in funding in future, focusing on innovative healthcare solutions. This influx of investment will likely spur advancements in external counterpulsation technology, leading to improved device efficacy and patient outcomes. As research progresses, new applications for these devices may emerge, further expanding their market potential.
Please Note: The report will take approximately 4–6 weeks to prepare and deliver.
Update cycle typically involves:
Dataset refresh & triangulation from credible public sources + paid databases where applicable.
Competitive mapping (platform coverage, business model, revenue/traffic proxies where available, key vertical splits)
Validation pass to ensure numbers are directionally consistent (and avoid “stale” assumptions)
Finalizing the PDF + Excel with clear assumptions and definitions.
Table of Contents
95 Pages
- 1. Australia External Counterpulsation Devices Size Share Growth Drivers Trends Opportunities & – Market Overview
- 1.1. Definition and Scope
- 1.2. Market Taxonomy
- 1.3. Market Growth Rate
- 1.4. Market Segmentation Overview
- 2. Australia External Counterpulsation Devices Size Share Growth Drivers Trends Opportunities & – Market Size (in USD Bn), 2019-2024
- 2.1. Historical Market Size
- 2.2. Year-on-Year Growth Analysis
- 2.3. Key Market Developments and Milestones
- 3. Australia External Counterpulsation Devices Size Share Growth Drivers Trends Opportunities & – Market Analysis
- 3.1. Growth Drivers
- 3.1.1 Increasing prevalence of cardiovascular diseases in Australia
- 3.1.2 Rising awareness of non-invasive treatment options
- 3.1.3 Technological advancements in external counterpulsation devices
- 3.1.4 Supportive government health initiatives promoting cardiac care
- 3.2. Restraints
- 3.2.1 High initial costs of external counterpulsation devices
- 3.2.2 Limited reimbursement policies for non-invasive treatments
- 3.2.3 Competition from alternative cardiac therapies
- 3.2.4 Regulatory challenges in device approval
- 3.3. Opportunities
- 3.3.1 Expansion of outpatient rehabilitation programs
- 3.3.2 Increasing investment in cardiovascular research
- 3.3.3 Collaborations between healthcare providers and device manufacturers
- 3.3.4 Growing demand for home-based cardiac care solutions
- 3.4. Trends
- 3.4.1 Shift towards personalized medicine in cardiac care
- 3.4.2 Integration of telemedicine in rehabilitation programs
- 3.4.3 Rising adoption of wearable health technology
- 3.4.4 Focus on preventive healthcare measures
- 3.5. Government Regulation
- 3.5.1 Australian Therapeutic Goods Administration (TGA) guidelines
- 3.5.2 Compliance with medical device safety standards
- 3.5.3 Regulations on clinical trials for new devices
- 3.5.4 Policies supporting innovation in medical technologies
- 3.6. SWOT Analysis
- 3.7. Stakeholder Ecosystem
- 3.8. Competition Ecosystem
- 4. Australia External Counterpulsation Devices Size Share Growth Drivers Trends Opportunities & – Market Segmentation, 2024
- 4.1. By Product Type (in Value %)
- 4.1.1 Portable External Counterpulsation Devices
- 4.1.2 Stationary External Counterpulsation Devices
- 4.1.3 Accessories and Consumables
- 4.1.4 Software Solutions
- 4.1.5 Others
- 4.2. By End-User (in Value %)
- 4.2.1 Hospitals
- 4.2.2 Outpatient Clinics
- 4.2.3 Rehabilitation Centers
- 4.2.4 Home Care Settings
- 4.3. By Technology (in Value %)
- 4.3.1 Pneumatic Systems
- 4.3.2 Electromechanical Systems
- 4.4. By Distribution Channel (in Value %)
- 4.4.1 Direct Sales
- 4.4.2 Distributors
- 4.4.3 Online Sales
- 4.5. By Region (in Value %)
- 4.5.1 New South Wales
- 4.5.2 Victoria
- 4.5.3 Queensland
- 4.5.4 Western Australia
- 4.5.5 South Australia
- 4.5.6 Tasmania
- 4.5.7 Northern Territory
- 5. Australia External Counterpulsation Devices Size Share Growth Drivers Trends Opportunities & – Market Cross Comparison
- 5.1. Detailed Profiles of Major Companies
- 5.1.1 CardioFlow Technologies
- 5.1.2 ECP Medical
- 5.1.3 HeartWave Solutions
- 5.1.4 PulseMed Devices
- 5.1.5 CardioPulse Innovations
- 5.2. Cross Comparison Parameters
- 5.2.1 No. of Employees
- 5.2.2 Headquarters
- 5.2.3 Inception Year
- 5.2.4 Revenue
- 5.2.5 Production Capacity
- 6. Australia External Counterpulsation Devices Size Share Growth Drivers Trends Opportunities & – Market Regulatory Framework
- 6.1. Medical Device Standards
- 6.2. Compliance Requirements and Audits
- 6.3. Certification Processes
- 7. Australia External Counterpulsation Devices Size Share Growth Drivers Trends Opportunities & – Market Future Size (in USD Bn), 2025-2030
- 7.1. Future Market Size Projections
- 7.2. Key Factors Driving Future Market Growth
- 8. Australia External Counterpulsation Devices Size Share Growth Drivers Trends Opportunities & – Market Future Segmentation, 2030
- 8.1. By Product Type (in Value %)
- 8.2. By End-User (in Value %)
- 8.3. By Technology (in Value %)
- 8.4. By Distribution Channel (in Value %)
- 8.5. By Region (in Value %)
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
